Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.37 |
| ▸ | FAP | Q12884 | 5/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874830 | 0.90 | DPP4 (0.46) | DPP4FAPDPP9CHRM1 | |
| Trifluoroacetic Acid SCHEMBL3877567 | 0.87 | DPP4 (0.37) | DPP4FAPDPP9CHRM1 | |
| SCHEMBL13866950 | 0.85 | DPP4 (0.38) | DPP4FAPDPP9HTR3ACHRM1 | |
| Trifluoroacetic Acid SCHEMBL3875531 | 0.82 | DPP4 (0.39) | DPP4FAPDPP9CHRM1 | |
| Trifluoroacetic Acid SCHEMBL3875625 | 0.81 | DPP4 (0.38) | DPP4FAPDPP9 | |
| SCHEMBL13866918 | 0.79 | DPP4 (0.44) | DPP4FAPDPP9HTR3A | |
| SCHEMBL3947405 | 0.79 | DPP4 (0.41) | DPP4FAPDPP9CHRM1 | |
| SCHEMBL13866946 | 0.78 | DPP4 (0.43) | DPP4FAPDPP9HTR3ACHRM1 | |
| SCHEMBL3881063 | 0.77 | DPP4 (0.42) | DPP4FAPDPP9CHEK1 | |
| Trifluoroacetic Acid SCHEMBL3874196 | 0.76 | DPP4 (0.48) | DPP4FAPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524847-B2 | Fused 1,3-dihydro-imidazole ring compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20060111362-A1 | 1,3-Dihydroimidazole ring compound | EISAI CO., LTD. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1568699-A1 | 1,3-DIHYDROIMIDAZOLE FUSED-RING COMPOUND | Eisai Co., Ltd. (JP) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111362-A1 | 1,3-Dihydroimidazole ring compound | NR2C2, NR0B2, DPP4 | DPP4 3/4885FAP 4451/4885EGFR 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.